Update on endocrine therapy for breast cancer.

  title={Update on endocrine therapy for breast cancer.},
  author={Aman U. Buzdar and Gabriel N Hortobagyi},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={4 3},
The choice of endocrine agent for breast cancer depends on the menopausal status of the patient, the stage of disease, prognostic factors, and the toxicity profile of the agent. Endocrine therapies are typically given sequentially, with the least toxic therapy given first. Tamoxifen is considered first-line endocrine therapy for all stages of breast cancer. New antiestrogens in development include nonsteroidal agents related to tamoxifen and pure steroidal antiestrogens. Luteinizing hormone… CONTINUE READING